The NZSE is deeply concerned by the recent decision by Aotearoa New Zealand Health Minister, Hon Simeon Brown, to ban the use of gonadotropin-releasing hormone analogues for the treatment of gender dysphoria or incongruence. Along with several other national societies, institutions, and experts that have released statements on this matter, we feel this is a completely inappropriate and unjustified response and will lead to harm.

Gonadotropin-releasing hormone analogues have been used for many years to suppress puberty in this context, and are used effectively in several other contexts. The available evidence and experience illustrates benefits beyond mental health and does not raise concerns around safety. While we support and agree with the need for further research to improve all clinical practice, it is unjustifiable to deny access while we await these data.

The NZSE values the insights and experience of gender diverse individuals and is concerned that these voices, and the opinions of NZ clinicians, were ignored during the consultation process undertaken prior to making this decision. Clinical decisions should always be made by clinicians, patients, and their whānau, and not by politicians on ideological grounds. To allow practice in Aotearoa New Zealand to align with established best practice and international guidelines, and to allow NZ clinicians to best support younger gender diverse New Zealander’s we support the repeal of this unethical ban at the earliest opportunity.